LENSAR, Inc. (LNSR) Misses Q3 EPS by 6c; Reports Cash and Cash Equivalents of $32.3M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/27/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
- TD Cowen: 'Sober View Suggests Structural Alcohol Risks Are Overblown'
- Needham Starts NeoVolta (NEOV) at Buy
- S&P 500 ends lower; chips tumble and Moderna rallies
- Hut 8 Mining Corp. (HUT) PT Raised to $55 at KBW As Management Delivers
- UBS trims AI portfolio exposure to semis and hardware after recent rally
LENSAR Reports Third Quarter 2021 Financial Results and Provides Business Update
November 8, 2021 7:00 AM ESTThird Quarter 2021 Procedure Volumes Increase 23% over 2020 Levels
Cash and Cash Equivalents of $32.3 Million reflect Cash Utilization of $2.2 Million in the Quarter
ORLANDO, Fla.--(BUSINESS WIRE)-- LENSAR, Inc. (Nasdaq: LNSR) (LENSAR or the Company), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter ended September 30, 2021 and provided an update on key strategic and operational initiatives.
The third quarter was one of continued progress on both the commercial and research and... More
